All In MedTech

Device Trial Radar · NCT05978180

Safety of Use and Efficacy of Pandora for Patients Suffering From Gonarthrosis (PANDORA2)

Prospective, Multicenter, Randomized, Parallel Groups Study Comparing the Safety and the Efficacy of the Administration of One Intra-articular Injection of 4.8 ml (HO-1) or Three Intra-articular Injections of 2.2 ml (HS-3) of Pandora Gel to One Intra-articular Injection of 2.5 ml (SINOVIAL®ONE), in Symptomatic Gonarthrosis

Last checked: Nov 19, 2026Latest source record: Dec 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 252 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

252

Actual

Start

Oct 18, 2023

Primary completion

Nov 13, 2025

Study completion Nov 13, 2025

Sponsor

Lead sponsor
LabrhaNot on our public-company list
Sponsor type
Industry
Collaborators
Statitec
First posted
Aug 7, 2023

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 35 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The knee osteoarthritis is a frequent degenerative condition that mainly affects subjects over 60, population often weakened by numerous comorbidities and concomitant treatments, justifying the development of new therapies. The viscosupplementation is a symptomatic treatment for knee osteoarthritis ; the objective of this intra-articular injection of hyaluronic acid is to reduce knee pain and improve mobility. In practice, there are two protocols to administer viscosupplementation : in a single injection or in three injections performed weekly. The present clinical investigation has the objective to evaluate the safety and efficacy of use of Pandora, a hyaluronic acid associated with tranexamic acid, in a single injection (HO-1) or in three injections performed weekly (HS-3), compared to a referred and commercialized medical device.

Conditions

  • Knee Osteoarthritis

Interventions

  • Medical Device : HO-1Device

    The injection will be performed at Day 1.

  • Medical Device : HS-3Device

    The three injections will be performed at Days 1, 8 and 15.

  • Medical Device : SINOVIAL® ONEDevice

    The injection will be performed at Day 1.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate the efficacy of the two medical devices containing Pandora gel, HO-1 and HS-3, on walking pain in the target knee, compared to the SINOVIAL® ONE.Time frame: 6 months

Locations

35 sites in 2 countries. Site status is shown where the registry gives one.

  • Cabinet de Rhumatologie

    Annecy, France

  • Centre de Chirurgie Orthopédique du Beaujolais

    Arnas, France

  • Centre de Médecine du Sport du Beaujolais

    Arnas, France

32 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.